---
title: "Telix Presents Phase 2 OPTIMAL-PSMA Dosimetry Data For TLX597-Tx In Prostate Cancer Treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284874178.md"
description: "Telix Pharmaceuticals Limited presented dosimetry data from the Phase 2 OPTIMAL-PSMA trial for TLX597-Tx, a radioligand therapy for metastatic castration-resistant prostate cancer. The trial, involving 120 men, showed low uptake in salivary glands and kidneys, supporting a dose-intensification regimen to enhance treatment effectiveness and reduce side effects. The company is also launching a Phase 2 study for androgen pathway-sensitive prostate cancer and advancing TLX591-Tx in a Phase 3 trial. TLX stock closed at $11.00, up 5.47%, and is trading at $11.20 in the overnight market, up 1.82%."
datetime: "2026-05-01T07:40:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284874178.md)
  - [en](https://longbridge.com/en/news/284874178.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284874178.md)
---

# Telix Presents Phase 2 OPTIMAL-PSMA Dosimetry Data For TLX597-Tx In Prostate Cancer Treatment

(RTTNews) - Telix Pharmaceuticals Limited (TLX), a commercial-stage biopharmaceutical company, on Thursday presented dosimetry data from the Phase 2 OPTIMAL-PSMA trial for TLX597-Tx in treating metastatic castration-resistant prostate cancer (mCRPC).

TLX597-Tx is a small molecule, PSMA-targeting, radioligand therapy (RLT) candidate designed to treat earlier-stage prostate cancer.

The Phase 2 OPTIMAL-PSMA is an open-label, multi-center, randomized, investigator-initiated trial (IIT), led by Professor Louise Emmett to evaluate the efficacy of TLX597-Tx. Conducted on 120 men with advanced mCRPC, the study utilizes a novel dose-intensification regimen, which increases the radiation dosage delivered to cancerous lesions when the tumors are the most vulnerable to improve overall effectiveness of the treatment.

Initial dosimetry data suggests low uptake by the salivary glands and kidneys, supporting dose intensification. By reducing radiation exposure in these healthy organs, the treatment prevents unwanted side effects like xerostomia and renal toxicity. In addition to better tolerability, the drug shows higher tumor uptake levels when compared to existing PSMA RLTs.

The company is also initiating OPTIMAL-E, a Phase 2 study in androgen pathway-sensitive prostate cancer (mHSPC), and is simultaneously advancing TLX591-Tx, a radio antibody-drug conjugate (rADC) in the Phase 3 ProstACT Global trial for treating mCRPC.

TLX closed Thursday at $11.00, up 5.47%. In the overnight market, the stock is trading at $11.20, up 1.82%.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [TLX.US](https://longbridge.com/en/quote/TLX.US.md)
- [TLX.AU](https://longbridge.com/en/quote/TLX.AU.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches | TLX Stock News](https://longbridge.com/en/news/286547990.md)
- [A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Recent FDA And Pipeline Milestones](https://longbridge.com/en/news/286344088.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)
- [Onconetix Advances Proclarix Clinical Validation and Market Expansion](https://longbridge.com/en/news/286404226.md)
- [Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026 | PFE Stock News](https://longbridge.com/en/news/286767626.md)